{"id": "1334621426565881856", "creation": 1607033518.0, "user_id": "65890224", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 0, "quote_count": 0}}, "text": "Durability of responses after #Moderna\u2019s #COVID19 #mRNA #vaccine reported in #NEJM today. New findings provide support for the use of a 100-\u03bcg dose in an ongoing phase 3 trial, which has recently shown a 94.5% efficacy rate in an interim analysis. #corona\u2026https://t.co/eWto9abvYR", "first_save": 1634559108.199414, "hashtags": ["#MODERNA", "#COVID19", "#MRNA", "#VACCINE", "#NEJM", "#CORONA"]}